Denali Therapeutics (DNLI) Return on Sales (2018 - 2024)

Denali Therapeutics (DNLI) has 7 years of Return on Sales data on file, last reported at 3.31% in Q2 2024.

• Return on Sales for Q2 2024 came in at 3.31%, down 332.0% year-over-year; the trailing twelve-month figure through Jun 2024 was 3.31% (down 331.0% YoY), and the FY2023 annual result was 0.0%, up 95.0% from the prior year.
• Return on Sales slipped to 3.31% in Q2 2024 per DNLI's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q4 2020 and troughed at 700.41% in Q1 2021.
• A 5-year average of 46.56% and a median of 0.08% in 2021 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2021 and 2022: Return on Sales slumped 68949 bps in 2021, then jumped 70039 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 0.01% in 2020, then tumbled by 878 bps to 0.06% in 2021, then plunged by 64 bps to 0.1% in 2022, then soared by 96 bps to 0.0% in 2023, then sank by 75286 bps to 3.31% in 2024.
• Business Quant data shows DNLI's Return on Sales at 3.31% in Q2 2024, 0.0% in Q1 2024, and 0.0% in Q4 2023.